Menu
Back to Journals » Cancer Management and Research » Volume 12
Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China [Corrigendum]
Authors Peng W, Zhang F, Wang Z , Li D , He Y, Ning Z, Sheng L, Wang J, Xia X, Yu C, Wang Z, Zhao Y, Liang H, Hu B, Sun C, Wang D, Cheng Y, Pan M, Xia L, Guo X, Zhang Y, Hu Z, Li X, Lu L, Zhang J, Qian H, Xie H, Sun G
Received 27 August 2020
Accepted for publication 27 August 2020
Published 11 September 2020 Volume 2020:12 Pages 8409—8410
Peng W, Zhang F, Wang Z, et al. Cancer Manag Res. 2020;12:6977—6985.
Page 6980, Effectiveness, second paragraph, last sentence, the text “In third-line and above, the DCR was 81.82% vs 76.59% with no significant difference between the two treatment groups (Table 2)” should read “In third-line and above, the DCR was 74.23% vs 81.82% with no significant difference between the two treatment groups (Table 2)”.
The data in Table 2 on page 6980 is incorrect. The correct Table 2 is shown below.
The authors apologize for these errors and advise they do not affect the results of the paper.
© 2020 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.